7.19

1.51% -0.11

After Hours: 7.22 0.03 +0.42%

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $7.19, with a volume of 522.21K. It is down -1.51% in the last 24 hours and down -32.80% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$7.30

Open:

$7.3

24h Volume:

522.21K

Relative Volume:

0.54

Market Cap:

$410.80M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-2.703

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

-5.15%

1M Performance:

-32.80%

6M Performance:

+69.58%

1Y Performance:

+13.23%

1-Day Range:

$7.10

$7.37

1-Week Range:

$6.96

$7.7099

52-Week Range:

$2.235

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (624)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	7.19	417.09M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

05:03 AM

2026 world cup analysis rankings: Will 4D Molecular Therapeutics Inc. stock gain from strong economy2026 world cup usa national team round of 32 defensive leaders counter attacking winner prediction expert opinion - Улправда

05:03 AM

Jan 05, 2026

Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com

Jan 05, 2026

Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com

Jan 05, 2026

Jan 01, 2026

4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN

Jan 01, 2026

Dec 27, 2025

Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz

Dec 27, 2025

Dec 24, 2025

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Nigeria

Dec 24, 2025

Dec 23, 2025

4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance

Dec 23, 2025

4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS

Dec 23, 2025

Dec 21, 2025

4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com

Dec 21, 2025

How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда

Dec 21, 2025

Dec 20, 2025

Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Dec 20, 2025

Dec 19, 2025

Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - Улправда

Dec 19, 2025

4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets

Dec 19, 2025

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha

Dec 19, 2025

Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber

Dec 19, 2025

Is 4D Molecular Therapeutics Inc. stock a top momentum playJuly 2025 Action & Long Hold Capital Preservation Tips - DonanımHaber

Dec 19, 2025

Analysts Are Bullish on Top Healthcare Stocks: Novan (NOVN), 4D Molecular Therapeutics (FDMT) - The Globe and Mail

Dec 19, 2025

What insider trading reveals about 4D Molecular Therapeutics Inc. stockQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - DonanımHaber

Dec 19, 2025

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Novan (NOVN) - The Globe and Mail

Dec 19, 2025

Stock Market Recap: Is 4D Molecular Therapeutics Inc. stock a top momentum playQuarterly Portfolio Report & Accurate Buy Signal Notifications - DonanımHaber

Dec 19, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Buy” Rating at Chardan Capital - Defense World

Dec 19, 2025

Dec 18, 2025

Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - Nasdaq

Dec 18, 2025

What dividend safety score for 4D Molecular Therapeutics Inc. stockJuly 2025 Action & Long-Term Investment Growth Plans - Улправда

Dec 18, 2025

4D Molecular Therapeutics : 710 AEROW Interim Phase 1 Data & Program Update (610855) - marketscreener.com

Dec 18, 2025

Dec 17, 2025

4D Molecular posts Phase 1 trial data for cystic fibrosis drug - Seeking Alpha

Dec 17, 2025

4D Molecular Therapeutics Announces Positive Interim Clinical Data from 4D-710 Aerow Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - marketscreener.com

Dec 17, 2025